Sales & Marketing News | pharmaphorum

News

AbbVie closes on Rinvoq approval in inflamed artery disease

AbbVie's Rinvoq is poised to become the first oral targeted treatment for giant cell arteritis in the EU after being backed by the CHMP.

News

Indivior changes CEO after warning sales will fall in 2025

UK-listed pharma company Indivior has appointed pharma veteran Joe Ciaffoni as its new chief executive, replacing Mark Crossley.

News

Lilly unveils $27bn reshoring drive around four new plants

Trump threatened tariffs if businesses do not reshore production to the US - and Lilly has now revealed a $27bn spend on new domestic facilities.

News

Can Keytruda finally break into early head and neck cancer?

The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.

News

Lilly launches discounted high-strength Zepbound vials in US

Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.

News

FDA looks at Opdivo/Yervoy in first-line colorectal cancer

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.

AbbVie closes on Rinvoq approval in inflamed artery disease

Indivior changes CEO after warning sales will fall in 2025

Lilly unveils $27bn reshoring drive around four new plants

Can Keytruda finally break into early head and neck cancer?

Lilly launches discounted high-strength Zepbound vials in US

FDA looks at Opdivo/Yervoy in first-line colorectal cancer

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks